Dr. Tasian on Challenges in Treating Pediatric Patients With Ph-Like ALL

Sarah K. Tasian, MD
Published: Tuesday, Sep 18, 2018



Sarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia, discusses the challenges in treating pediatric patients with Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL).

One of the first hurdles in the treatment paradigm is genetic diagnostics, explains Tasian. Physicians have to be able to identify these patients relatively quickly. Induction therapy, which consists of 1 month of chemotherapy, is never altered for patients, states Tasian. Nonetheless, physicians have to be able to identify these patients before the end of induction therapy in order to introduce other therapeutic agents. Currently used therapies include tyrosine kinase inhibitors (TKIs).

Another challenge in pediatric oncology as a whole, says Tasian, is access to novel therapies. Recently, more pharmaceutical companies have shown interest in partnering with physicians to facilitate access to novel therapies like TKIs for patients, says Tasian.
SELECTED
LANGUAGE


Sarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia, discusses the challenges in treating pediatric patients with Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL).

One of the first hurdles in the treatment paradigm is genetic diagnostics, explains Tasian. Physicians have to be able to identify these patients relatively quickly. Induction therapy, which consists of 1 month of chemotherapy, is never altered for patients, states Tasian. Nonetheless, physicians have to be able to identify these patients before the end of induction therapy in order to introduce other therapeutic agents. Currently used therapies include tyrosine kinase inhibitors (TKIs).

Another challenge in pediatric oncology as a whole, says Tasian, is access to novel therapies. Recently, more pharmaceutical companies have shown interest in partnering with physicians to facilitate access to novel therapies like TKIs for patients, says Tasian.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x